Schall Thomas J.
- SEC CIK
- 0001423084
In the past year, 1 open-market purchase filing worth $101.1K and no sales.
Current role at each company
- IMRX Immuneering CorpDirectoras of Jun 11, 2026
- ChemoCentryx, Inc.President and CEOas of Oct 24, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $101.1K
- 1 filing
- Sold
- –
- 0 filings
- Net
- +$101.1K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Schall Thomas J. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
IMRX Immuneering Corp
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | Schall Thomas J.Director | PPurchaseClass A Common Stock | +21.6K | $4.67 | +$101.1K | +40.9%74.5K after | |
| Jun 30, 2025 (view filing) | Jun 27 | 3 days | Schall Thomas J.Director | PPurchaseClass A Common Stock | +9.50K | $3.66 | +$34.8K | +21.9%52.9K after | |
| Jun 18, 2025 (view filing) | Jun 17 | 1 day | Schall Thomas J.Director | PPurchaseClass A Common Stock | +40.5K | $2.21 | +$89.5K | +1,396.0%43.4K after | |
| Mar 25, 2024 (view filing) | Mar 22 | 3 days | Schall Thomas J.Director | PPurchaseClass A Common Stock | +2.90K | $2.55 | +$7.39K | New position2.90K after |
ChemoCentryx, Inc.
President and CEO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 8, 2022 (view filing) | Aug 4 | 4 days | Schall Thomas J.President and CEO | SSale | −130.0K | $50.24 | −$6.53M | −5.2%2.39M after |